Latest Regulatory Approval News

Minerals 260 Limited has launched a $200-$220 million public offer to fund the acquisition of the Bullabulling Gold Project in Western Australia, featuring a 2.3 million ounce JORC-compliant resource. The company seeks ASX re-admission following a significant change in scale of activities.

Nyrada Inc. posted a significant $2.46 million loss for H1 FY25, driven by increased R&D spend, while advancing its lead drug NYR-BI03 into first-in-human trials following regulatory approval.

Zelira Therapeutics has received a $1.15 million cash refund from the Australian Government’s R&D Tax Incentive Scheme, bolstering its working capital to advance clinical development and business operations.

Ausmon Resources has completed critical field reconnaissance across three South Australian tenements, setting the stage for a targeted rare earth elements drilling program pending regulatory approval.

Propel Funeral Partners has agreed to acquire two historic New Zealand funeral service providers, marking a strategic expansion into new regional markets with an acquisition valued at up to A$7.3 million.

Adriatic Metals has announced a two-tranche institutional placement to raise A$80 million, aiming to fast-track the expansion of its Vares Processing Plant and strengthen its balance sheet ahead of commercial production.

SG Fleet Group Limited reported a 9.8% drop in half-year profit to $41.1 million, while announcing a $3.50 per share acquisition scheme by Pacific Equity Partners' vehicle Westmann Bidco.

Opthea has completed the final patient visit in its pivotal COAST Phase 3 trial evaluating sozinibercept combined with aflibercept for wet AMD, with topline results expected early Q2 2025.

Maximus Resources Limited has issued a Target's Statement recommending shareholders accept Astral Resources NL's off-market takeover bid, which offers a significant premium and improved liquidity. The offer, valuing Maximus shares at approximately $0.073 each, aims to consolidate gold assets in Western Australia under Astral's larger portfolio.

PYC Therapeutics has launched a A$145.8 million pro-rata accelerated non-renounceable entitlement offer to fund late-stage clinical trials across its pipeline targeting rare diseases with high unmet needs. The capital raise aims to extend the company’s cash runway beyond FY27, supporting four drug candidates through critical human safety and efficacy milestones.

Memphasys has initiated clinical utility testing of its Felix™ System in Brazil through a partnership with Laboratorio Androscience, aiming to establish a foothold in the rapidly growing Latin American IVF sector.

E79 Gold Mines has successfully raised $1.8 million through a placement oversubscribed by more than double, aiming to fund exploration at its promising Laverton South Gold Project and bolster working capital.